Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications

        Print
| Source: Active Biotech AB
Lund,  Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces  that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release
here)  will  initiate  a  new  phase  II,  proof-of-concept  clinical trial with
tasquinimod  in  a  so-called  umbrella  study  evaluating  the compound in four
different tumor types.

The  study will evaluate the  safety and efficacy of  tasquinimod in advanced or
metastatic  hepato-cellular,  ovarian,  renal  cell  and  gastric  carcinomas in
patients who have progressed after standard therapies.



About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases  and cancer. Projects  in or entering
pivotal  phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for  prostate  cancer  as  well  as  ANYARA  for use in cancer targeted therapy,
primarily  of  renal  cell  cancer.  In  addition,  laquinimod  is  in  Phase II
development for Crohn's and Lupus. An additional project in clinical development
is  the orally administered compound 57-57 for Systemic Sclerosis.  Please visit
www.activebiotech.com for more information.


For further information:


Active Biotech
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson@activebiotech.com

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 7:00 a.m. CET on October 19, 2012. 

[HUG#1650576]